Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress

Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress

MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides a market update on its commercial and operational performance for the quarter ended June 30, 2026 (Q2 2026).

Telix Pharmaceuticals: Q2 2026 revenue jumps 21%

Telix Pharmaceuticals also provided an update on its key clinical pipeline and new partnerships. The post Telix Pharmaceuticals: Q2 2026 revenue jumps 21% appeared first on The Motley Fool Australia.

Telix reports Q2 revenue of US$247m

MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") provides a market update on its commercial and operational performance for the quarter ended June 30, 2026 (Q2 2026). Q2 2026 Highlights[1] Group revenue of US$247 million, up 7% quarter-over-quarter (QoQ) and up 21% year-over-year (YoY). Precision Medicine continues to deliver strong growth, revenue of US$202 mil…

Telix Pharmaceuticals (ASX:TLX) Revenue Nears US$1bn as Phase 3 Catalyst Gets Cleared

US$1bn Revenue Run-Rate Could Unlock the Next Re-Rate Telix Pharmaceuticals has given investors renewed confidence that the business is entering the next stage of its growth story. We have covered Telix extensively and initiated a Buy rating in April while also purchasing shares ourselves. Since our last report, the stock has rallied more than 40%, supported by continued operational execution. The latest update further strengthened that thesis. …

Telix Pharmaceuticals Posts $247M Q2 Revenue, Up 21% YoY Fueled by PSMA Imaging Growth

Telix Q2 2026 Revenue US$247M, Strong Momentum and Pipeline Progress

Telix Q2 2026 Revenue US$247M, Strong Momentum and Pipeline Progress Melbourne (Australia) and Indianapolis, IN (United States) | July 21, 2026 Telix provides a market update on its commercial and operational performance for the quarter ended June 30, 2026 (Q2 2026). Q2 2026 Highlights[1] Group revenue of US$247 million, up 7% quarter-over-quarter (QoQ) and up 21% year-over-year (YoY). Precision Medicine continues to deliver strong growth, …